Fingerprint
Dive into the research topics of 'Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy - The P-SELECT trial (WJOG10617G) - A randomised phase II trial by the West Japan Oncology Group'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically